Immunology

Shaperon is a biotechnology company specializing in immunomodulatory platform-based drug development, established in 2008.

he company holds the world’s first drug development platform targeting GPCR19 to inhibit the activation of the P2X7R-NLRP3 inflammasome complex, and it has also established a nanobody-based antibody development platform designed to overcome the limitations of conventional bispecific antibodies and antibody-drug conjugates.

Shaperon possesses the capabilities to carry out the entire drug development process from early candidate discovery to Phase 3 clinical trials, and has demonstrated its commercialization potential through two successful technology transfer deals. The company is also actively researching a broad pipeline of innovative therapeutics, including next-generation inflammasome inhibitors, immuno-oncology agents, antibody-drug conjugates (ADCs), and radioimmunotherapy (RPT) technologies, in pursuit of sustainable growth.

In particular, AIDEN, an AI-based drug development platform developed by AIMCE center, significantly enhances the success rate and speed of drug development through advanced AI training data and proprietary algorithms. The platform optimizes candidate development using its AI cytotoxicity algorithm, which achieves an accuracy rate of 92%.

Shaperon is currently developing a range of immune therapeutics targeting various immune-related diseases, including atopic dermatitis, Alzheimer’s disease, idiopathic pulmonary fibrosis, alopecia areata, and obesity. With an innovative therapeutic pipeline that includes immune checkpoint inhibitor bispecific antibodies and coronavirus neutralizing antibodies, the company is strengthening its competitiveness in the global market.